Back to search
FDAFDA · Food and drugs·Recall number Z-1879-2017

Pressure Injectable Arrowg+ard Blue Plus Multi-Lumen Central Venous Catheterization Kit. Permits venous access to central circulation by way of subclavian, jugular and femoral veins. The ARROWg+ard technology is intended to provide protection against catheter-related bloodstream infections (CRBSIs). It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). Clinical effectiveness of the ARROW g+ard Blue Plus catheter in preventing CRBSIs compared to the original ARROWg+ard Blue catheter has not been studied

Published May 3, 2017 · Recall initiated: March 17, 2017

Summary

FDA records medical device Class II recall Z-1879-2017, published May 3, 2017 and initiated March 17, 2017. Recalling firm: Arrow International Inc; Status: Terminated; Reported quantity: 310 units; Lot: Product Codes ASK-45703-PRWJ1, ASK-45703-PUAB1, and ASK-45703-PUPM Lot # 13F16L0105, 23F16K0180 and 13F16L0199. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Arrow International is recalling due to possible voids in the catheter hub, which could lead to an interlumen crossover.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Arrow International Inc
Distributor
US Distribution to NJ, IL, and PA
Lot
Product Codes ASK-45703-PRWJ1, ASK-45703-PUAB1, and ASK-45703-PUPM Lot # 13F16L0105, 23F16K0180 and 13F16L0199
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was Pressure Injectable Arrowg+ard Blue Plus Multi-Lumen Central Venous Catheterization Kit. Permits venous access to central circulation by way of subclavian, jugular and femoral veins. The ARROWg+ard technology is intended to provide protection against catheter-related bloodstream infections (CRBSIs). It is not intended to be used as a treatment for existing infections nor is it indicated for long-term use (>30 days). Clinical effectiveness of the ARROW g+ard Blue Plus catheter in preventing CRBSIs compared to the original ARROWg+ard Blue catheter has not been studied recalled?

Yes. FDA published recall Z-1879-2017 on May 3, 2017. Reported hazard: Arrow International is recalling due to possible voids in the catheter hub, which could lead to an interlumen crossover.

What should I do if I have this product?

Voluntary: Firm initiated · Letter